Key result
SGLT2 inhibitors reduced the risk of hospitalization for heart failure (HR 0.68; 95% CI 0.60-0.76; P<0.0001), whereas thiazolidinediones increased the risk (HR 1.45; 95% CI 1.18-1.78; P=0.0004).
Why the study?
Patients with type 2 diabetes mellitus frequently use multiple antihyperglycemic drugs, but the risk of heart failure hospitalization and the parallel effect of glucose-lowering across these combinations remain unpredictable.
Do different antihyperglycemic drugs and their combinations affect the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus?
Meta-Analysis
Do different antihyperglycemic drugs and their combinations affect the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus?
Hazard Ratio: 0.68 (95% CI 0.6–0.76)
p-value: p=< 0.0001
SGLT2 inhibitors reduce the risk of heart failure hospitalization in type 2 diabetes, whereas thiazolidinediones increase it, and overall glucose lowering provides an additive benefit.
No takes yet. Share an insight, caveat, or question.
Supports SGLT2 inhibitor preference and thiazolidinedione avoidance in diabetes with HF risk; confirms opposing class effects on hospitalization.
Cintra et al. (2021) conducted a meta-analysis in type 2 diabetes mellitus. SGLT2 inhibitors vs. Other antihyperglycemic drugs or placebo was evaluated on Hospitalization resulting from heart failure (HHF) (HR 0.68, 95% CI 0.60-0.76, p=< 0.0001). SGLT2 inhibitors reduced the risk of hospitalization for heart failure (HR 0.68; 95% CI 0.60-0.76; P<0.0001), whereas thiazolidinediones increased the risk (HR 1.45; 95% CI 1.18-1.78; P=0.0004).